Patient perceptions of insulin detemir as reported through patient telephone surveys

Current Medical Research and Opinion

Volumn 23, Issue 9, 2007, Pages 2043-2049

  Kerney, Donna L ^a   Paradis, Diana ^a   Brunton, Stephen ^b  

^a InfoMedics Inc   (United States)

^b AMERICAN ACADEMY OF FAMILY PHYSICIANS   (United States)

Author keywords

Diabetes; Health surveys; Insulin detemir; Patient reported outcomes

Indexed keywords

GLIMEPIRIDE; INSULIN; INSULIN DETEMIR; INSULIN GLARGINE; METFORMIN; DRUG DERIVATIVE;

ADULT; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HEALTH BELIEF; HEALTH SURVEY; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MEDICAL INSTRUMENTATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT SATISFACTION; SIDE EFFECT; TELECONSULTATION; WEIGHT GAIN; WEIGHT REDUCTION; AGED; CROSS-SECTIONAL STUDY; INFORMATION PROCESSING; MIDDLE AGED; PATIENT; PSYCHOLOGICAL ASPECT; TELEPHONE;

AGED; BLOOD GLUCOSE; CROSS-SECTIONAL STUDIES; DATA COLLECTION; DIABETES MELLITUS; FEMALE; HUMANS; INSULIN; MALE; MIDDLE AGED; PATIENTS; TELEPHONE;

EID: 36048989676     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079907X219508     Document Type: Article

References (28)

1. American Diabetes Association. Total prevalence of diabetes and pre-diabetes. Available at: http://www.diabetes.org/diabetes-statistics/ prevalence.jsp. Accessed September 2006
2. National Center for Health Statistics. FASTSTATS A to Z. Diabetes. Available at: http://www.cdc.gov/nchs/fastats/diabetes.htm. Accessed September 2006
3. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86
4. National Institutes of Health. National Institute of Diabetes and Digestive and Kidney Diseases. National Diabetes Statistics. http://diabetes.niddk.nih.gov/dm/pubs/statistics/index.htm. Accessed September 2006
5. American Diabetes Association. Standards of Medical Care in Diabetes 2007. Diabetes Care 2007;30:S4-41
6. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care 2006;29:1963-72
7. Kamal AD, Dixon AN, Bain SC. Safety and side effects of the insulin analogues. Expert Opin Drug Saf 2006;5:131-43
8. Haak T, Tiengo A, Draeger E, et al. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Diabetes Obes Metab 2005;7:56-64
9. Raslova K, Bogoev M, Raz I, et al. Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes. Diabetes Res Clin Pract 2004;66:193-201
10. Heise T, Nosek L, Ronn BB, et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in subjects with type 1 diabetes. Diabetes 2004;53:1614-20
11. Klein O, Lynge J, Endahl L, et al. Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes. Diabetes Obes Metab 2007; 9:290-9
12. Home P, Bartley P, Russell-Jones DL, et al. Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes: a randomized clinical trial. Diabetes Care 2004;27:1081-7
13. Kolendorf K, Ross GP, Pavlic-Renar I, et al. Insulin detemir lowers the risk of hypoglycemia and provides more consistent plasma glucose levels compared with NPH insulin in type 1 diabetes. Diabet Med 2006;23:729-35
14. Pieber TR, Draeger E, Kristensen A, Grill V. Comparison of three multiple injection regimens for type 1 diabetes: morning plus dinner or bedtime administration of insulin detemir vs. morning plus bedtime NPH insulin. Diabet Med 2005;22:850-7
15. Pieber TR, Treichel HC, Hompesch B, et al. Comparison of insulin detemir and insulin glargine in subjects with Type 1 diabetes using intensive insulin therapy. Diabet Med 2007;24:635-42
16. Russell-Jones DL, Simpson R, Hylleberg B, et al. Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type 1 diabetes mellitus using a basal-bolus regimen. Clin Ther 2004;26:724-36
17. Hermansen K, Fontaine P, Kukolja K, et al. Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes. Diabetologia 2004;47:622-9
18. Hermansen K, Davies M, Derezinski T, et al. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naïve people with type 2 diabetes. Diabetes Care 2006;29:1269-74
19. Philis-Tsimikas A, Charpentier G, Clausen P, et al. Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes. Clin Ther 2006;28:1569-81
20. Rosenstock J, Davies M, Home PD, et al. Insulin detemir added to oral anti-diabetic drugs in type 2 diabetes provides glycemic control comparable to insulin glargine with less weight gain. Diabetes 2006;55:A132
21. Raslova K, Bogoev M, Raz I, et al. Corrigendum to: Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes. Diabetes Res Clin Pract 2004;66:193-201; 2006;72:112
22. Chaufan C. Patient compliance: in search of the real question in diabetes care. Am Fam Physician 2000;61:644-7
23. Oparil S, Calhoun DA. Managing the patient with hard-to-control hypertension. Am Fam Physician 1998;57:1007-14; 1019-20
24. Cushman WC, Reda DJ, Perry HM, et al., for the Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Regional and racial differences in response to antihypertensive medication use in a randomized controlled trial of men with hypertension in the United States. Arch Intern Med 2000,160:825-31
25. Dezii CM. Medication noncompliance: What is the problem? Manag Care 2000;9:7-12
26. Home P, Kurtzhals P. Insulin detemir: from concept to clinical experience. Expert Opin Pharmacother 2006;7:325-43
27. Meneghini LF, Rosenberg KH, Koenen C, et al. Insulin detemir improves glycémie control with less hypoglycemia and no weight gain in patients with type 2 diabetes who were insulin naïve or treated with NPH or insulin glargine: clinical practice experience from a German subgroup of the PREDICTIVE study. Diabetes Obes Metab 2007;9:418-27
28. Dornhorst A, Luddeke H-J, Sreenan S, et al. Safety and efficacy of insulin detemir in clinical practice: 14-week follow-up data from type 1 and type 2 diabetes patients in the PREDICTIVE European cohort. Int J Clin Pract 2007;61:523-8